AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

Group 1 - AstraZeneca Plc released topline data from the RESOLUTE Phase 3 trial of Fasenra (benralizumab), which showed numerical improvement but did not achieve statistical significance in the primary endpoint for patients with chronic obstructive pulmonary disease (COPD) [1] - The safety and tolerability profile for Fasenra in the trial was consistent with the known profile of the medicine [1] - Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA) in over 80 countries, including the US, Japan, the EU, and China [2] Group 2 - Fasenra has also been approved in more than 60 countries for the treatment of eosinophilic granulomatosis with polyangiitis and is under regulatory review for hypereosinophilic syndrome [3] - AstraZeneca shared high-level results from a pre-specified interim analysis of the Phase 3 TULIP-SC trial in patients with systemic lupus erythematosus (SLE), showing a statistically significant reduction in disease activity compared to placebo [4][5] - The TULIP-SC interim results are currently under regulatory review, and Saphnelo IV infusion is approved for moderate to severe SLE in over 70 countries [6]